Search Results - "Galoppin, Manon"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome by Rival, Manon, Galoppin, Manon, Thouvenot, Eric

    Published in Frontiers in immunology (27-04-2022)
    “…Radiologically Isolated Syndrome (RIS) is characterized by MRI-typical brain lesions fulfilling the 2009 Okuda criteria, detected in patients without clinical…”
    Get full text
    Journal Article
  2. 2

    Central inhibition of stearoyl-CoA desaturase has minimal effects on the peripheral metabolic symptoms of the 3xTg Alzheimer’s disease mouse model by Hamilton, Laura K., M’Bra, Paule E. H., Mailloux, Sophia, Galoppin, Manon, Aumont, Anne, Fernandes, Karl J. L.

    Published in Scientific reports (02-04-2024)
    “…Evidence from genetic and epidemiological studies point to lipid metabolism defects in both the brain and periphery being at the core of Alzheimer’s disease…”
    Get full text
    Journal Article
  3. 3

    Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications by Galoppin, Manon, Kari, Saniya, Soldati, Sasha, Pal, Arindam, Rival, Manon, Engelhardt, Britta, Astier, Anne, Thouvenot, Eric

    Published in Brain communications (04-07-2022)
    “…Abstract Vitamin D deficiency has been associated with the risk of multiple sclerosis, disease activity and progression. Results from in vitro experiments,…”
    Get full text
    Journal Article
  4. 4

    Chronic Neuroleptic‐Induced Parkinsonism Examined With Positron Emission Tomography by Galoppin, Manon, Berroir, Pierre, Soucy, Jean‐Paul, Suzuki, Yoshitaka, Lavigne, Gilles J., Gagnon, Jean‐François, Montplaisir, Jacques Y., Stip, Emmanuel, Blanchet, Pierre J.

    Published in Movement disorders (01-07-2020)
    “…Background Neuroleptic drug‐induced parkinsonism (NIP) is a leading cause of parkinsonism, particularly in aging. Based on abnormal dopamine transporter scan…”
    Get full text
    Journal Article
  5. 5